131 related articles for article (PubMed ID: 26584669)
1. An anthrax toxin variant with an improved activity in tumor targeting.
Wein AN; Peters DE; Valivullah Z; Hoover BJ; Tatineni A; Ma Q; Fattah R; Bugge TH; Leppla SH; Liu S
Sci Rep; 2015 Nov; 5():16267. PubMed ID: 26584669
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor activity of anthrax toxin variants that form a functional translocation pore by intermolecular complementation.
Liu S; Ma Q; Fattah R; Bugge TH; Leppla SH
Oncotarget; 2017 Sep; 8(39):65123-65131. PubMed ID: 29029417
[TBL] [Abstract][Full Text] [Related]
3. Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination.
Cao S; Guo A; Liu Z; Tan Y; Wu G; Zhang C; Zhao Y; Chen H
Infect Immun; 2009 Oct; 77(10):4679-87. PubMed ID: 19620345
[TBL] [Abstract][Full Text] [Related]
4. Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
Fischer ES; Campbell WA; Liu S; Ghirlando R; Fattah RJ; Bugge TH; Leppla SH
Protein Sci; 2019 Jun; 28(6):1059-1070. PubMed ID: 30942916
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin inhibition of anthrax lethal toxin.
Moayeri M; Wiggins JF; Lindeman RE; Leppla SH
Antimicrob Agents Chemother; 2006 Aug; 50(8):2658-65. PubMed ID: 16870755
[TBL] [Abstract][Full Text] [Related]
6. Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin.
Liu S; Redeye V; Kuremsky JG; Kuhnen M; Molinolo A; Bugge TH; Leppla SH
Nat Biotechnol; 2005 Jun; 23(6):725-30. PubMed ID: 15895075
[TBL] [Abstract][Full Text] [Related]
7. Tumor Imaging Using Radiolabeled Matrix Metalloproteinase-Activated Anthrax Proteins.
Elvina Xavier MA; Liu S; Bugge TH; Torres JB; Mosley M; Hopkins SL; Allen PD; Berridge G; Vendrell I; Fischer R; Kersemans V; Smart S; Leppla SH; Cornelissen B
J Nucl Med; 2019 Oct; 60(10):1474-1482. PubMed ID: 30954944
[TBL] [Abstract][Full Text] [Related]
8. Participation of residue F552 in domain III of the protective antigen in the biological activity of anthrax lethal toxin.
Khanna H; Gupta PK; Singh A; Chandra R; Singh Y
Biol Chem; 2001 Jun; 382(6):941-6. PubMed ID: 11501759
[TBL] [Abstract][Full Text] [Related]
9. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.
Suryanarayana N; Verma M; Thavachelvam K; Saxena N; Mankere B; Tuteja U; Hmuaka V
Appl Microbiol Biotechnol; 2016 Oct; 100(19):8439-51. PubMed ID: 27364624
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
Liu S; Wang H; Currie BM; Molinolo A; Leung HJ; Moayeri M; Basile JR; Alfano RW; Gutkind JS; Frankel AE; Bugge TH; Leppla SH
J Biol Chem; 2008 Jan; 283(1):529-540. PubMed ID: 17974567
[TBL] [Abstract][Full Text] [Related]
11. Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.
Liu S; Bugge TH; Frankel AE; Leppla SH
Methods Mol Biol; 2009; 539():175-90. PubMed ID: 19377974
[TBL] [Abstract][Full Text] [Related]
12. Anthrax lethal factor (LF) mediated block of the anthrax protective antigen (PA) ion channel: effect of ionic strength and voltage.
Neumeyer T; Tonello F; Dal Molin F; Schiffler B; Orlik F; Benz R
Biochemistry; 2006 Mar; 45(9):3060-8. PubMed ID: 16503661
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics simulations of complexes between wild-type and mutant anthrax protective antigen variants and a model anthrax toxin receptor.
Stiles L; Nelson DJ
J Biomol Struct Dyn; 2005 Apr; 22(5):503-19. PubMed ID: 15702923
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic activity of Bacillus anthracis protective antigen observed in a macrophage cell line overexpressing ANTXR1.
Salles II; Voth DE; Ward SC; Averette KM; Tweten RK; Bradley KA; Ballard JD
Cell Microbiol; 2006 Aug; 8(8):1272-81. PubMed ID: 16882031
[TBL] [Abstract][Full Text] [Related]
15. Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Peters DE; Hoover B; Cloud LG; Liu S; Molinolo AA; Leppla SH; Bugge TH
Toxicol Appl Pharmacol; 2014 Sep; 279(2):220-9. PubMed ID: 24971906
[TBL] [Abstract][Full Text] [Related]
16. Anthrax protective antigen cleavage and clearance from the blood of mice and rats.
Moayeri M; Wiggins JF; Leppla SH
Infect Immun; 2007 Nov; 75(11):5175-84. PubMed ID: 17724066
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of anthrax lethal factor microinjected into macrophage cells through Sendai virus envelopes.
Swain PK; Sarkar NK; Sharma M; Goel S; Singh RP; Singh Y
Indian J Biochem Biophys; 1997; 34(1-2):186-91. PubMed ID: 9343949
[TBL] [Abstract][Full Text] [Related]
18. Anti-proliferative role of recombinant lethal toxin of Bacillus anthracis on primary mammary ductal carcinoma cells revealing its therapeutic potential.
Khandia R; Pattnaik B; Rajukumar K; Pateriya A; Bhatia S; Murugkar H; Prakash A; Pradhan HK; Dhama K; Munjal A; Joshi SK
Oncotarget; 2017 May; 8(22):35835-35847. PubMed ID: 28415766
[TBL] [Abstract][Full Text] [Related]
19. Identification of new dominant-negative mutants of anthrax protective antigen using directed evolution.
Wu G; Feng C; Cao S; Guo A; Liu Z
Appl Biochem Biotechnol; 2012 Nov; 168(5):1302-10. PubMed ID: 22948605
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Substrate-selective Exosite within the Metalloproteinase Anthrax Lethal Factor.
Goldberg AB; Cho E; Miller CJ; Lou HJ; Turk BE
J Biol Chem; 2017 Jan; 292(3):814-825. PubMed ID: 27909054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
